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384Objective: To compare the outcome of donepezil treatment in ethnically diverse
Alzheimer disease (AD) patients with ethnically diverse AD patients who did not
receive donepezil. Methods: Patients meeting NINCDS-ADRA criteria for probable or
possible AD from a consortium of California sites were systematically followed for at
least 1 year in this prospective, observational study. Their treatment regimens,
including prescription of donepezil, were determined by their individual physician
according to his or her usual criteria. Patients self-identiﬁed their ethnicity. Results:
The 64 ethnically diverse AD patients who completed the study and received donepezil
treatment had an average 1-year decline of 2.30 points (standard deviation: 3.9) on
the 30-point Mini-Mental State Exam compared with a 1.70-point (standard devia-
tion: 4.2) decline in the 74 ethnically diverse completers who received no donepezil or
other anti-AD drugs during the study period. This difference was not statistically
signiﬁcant. The overall Cohen effect size of this treatment-associated difference was
estimated at e0.15. After using propensity analyses and other techniques to assess
factors that could bias prescribing decisions, the lack of beneﬁts associated with
donepezil treatment remained. The lack of donepezil beneﬁts also remained when
more traditional analyses were applied to these data. Conclusion: Ethnically diverse
AD patients in this study apparently did not beneﬁt from 1 year of donepezil treat-
ment. These unpromising results are in contrast to modest beneﬁts of donepezil
treatment measured in a directly comparable California study involving white non-
Latino AD patients. (Am J Geriatr Psychiatry 2015; 23:384e390)
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Tinklenberg et al.INTRODUCTION
In this prospective, observational study, we
compared the outcome of donepezil treatment in
ethnically diverse Alzheimer disease (AD) patients
with outcomes of ethnically diverse AD patients who
did not receive donepezil. All subjects identiﬁed for
this present study were part of a large-scale, ongoing
California investigation that included all ethnic
groups. We focused on ethnic minorities here to
address the relative lack of systematic information on
speciﬁc drug effects in ethnically diverse AD patients.
The methodology of this study was designed to
produce information useful to practicing clinicians.
The AD subjects included were those who would be
treated in a typical community setting; subjects were
not excluded for medical conditions, concomitant
medications, or other enrollment restrictions of tradi-
tional randomized clinical trials (RCTs) involving anti-
Alzheimer drugs. The overall intent was to provide
guidance for what individual physicians can expect in
their practices when donepezil treatment is prescribed
for 1 year in ethnically diverse AD patients.METHODS
Study Design
This study was designed to collect systematic data
from a prospective, longitudinal, multisite, observa-
tional study in California that would assess the
effectiveness of donepezil in ethnically diverse pa-
tients with AD. Patients were enrolled in the study
between January 1, 1998 and June 30, 2004. The
diagnosis of AD was made using the National Insti-
tute of Neurological and Communicative Disorders
and StrokeeAD and Related Disorders Association
criteria for probable or possible AD and Diagnostic
and Statistical Manual of Mental Disorders, Fourth Edi-
tion, criteria for AD.1,2 Men and women with AD
between 40 and 90 years of age were included.
Patients had Mini-Mental State Exam (MMSE)
scores of at least 10 and no more than 26,3 sufﬁcient
physical abilities to participate in the initial outpa-
tient diagnostic process, and a reliable caregiver who
agreed to participate in the research and either lived
with or closely monitored the patient. No patients
could be taking donepezil or any other anti-AD drugAm J Geriatr Psychiatry 23:4, April 2015at their baseline assessment or during the prior 4
weeks. All patients in this study identiﬁed their
ethnic status as Latino, African American, Asian
American, or otherwise ethnically diverse American.
After baseline assessment, each patient’s physician
determined treatment, including whether or not
donepezil was prescribed according to his or her
clinical judgment. All patients were expected to
participate in a structured clinic reassessment about 1
year after baseline. Donepezil treatment status over
the preceding year was conﬁrmed at this reassess-
ment. Depending on their clinical status, some pa-
tients were seen more frequently during the study
period. Patients who took any experimental drug,
any other anti-AD drug such as any other cholines-
terase inhibitors, or meantime throughout the study
period were excluded from the ﬁnal analyses.Study Sites
The 10 study sites included 8 California Alz-
heimer’s Disease Centers of California (CADCs;
Stanford/Palo Alto VA [the coordinating site], Uni-
versity of California Davis at Martinez, University of
California Davis at Sacramento, University of Cali-
fornia Irvine, University of California Los Angeles,
University of California San Diego, University of
California San Francisco, and University of Southern
California at Rancho) and 2 VA Mental Illness
Research and Education Centers in Northern Cali-
fornia (San Francisco and Palo Alto).
The CADC sites have been closely collaborating
and using common research data collection protocols
for over 20 years.4,5 Data were processed centrally
through the Institute for Health and Aging at the
University of California in San Francisco. To increase
intersite reliability and accuracy, training and recali-
bration exercises are held with case reports, videos,
and autopsy ﬁndings.4,6 The VA Mental Illness
Research and Education Center sites are also directed
by CADC consortium investigators and use the same
protocols. Patients are typically drawn from the
surrounding communities.
The sites strive to follow patients to autopsy and
systematically determine correlations between pre-
morbid clinical diagnoses and neuropathologic ﬁnd-
ings. All sites are experienced in conducting National
Institutes of Health and industry-sponsored collabo-
rative trials of anti-AD medications. This study was385
TABLE 1. Baseline Patient Characteristics
Donepezil Treatment No Donepezil Treatment
Completers (N [ 64)
Non-Completers
(N [ 37) Completers (N [ 74)
Non-Completers
(N [ 54)
mean  SD
Age, years 74.5  9.4 77.7  7.8 76.6  8.4 76.5  8.0
Age at symptom onset, years 69.6  10.8 73.2  8.1 72.0  8.6 72.3  8.2
Years of education 11.1  4.5 10.9  5.5 11.4  4.5 8.6  5.2
MMSE score 19.0  4.3 17.1  4.4 18.5  4.3 16.9  4.5
BRDRS score 4.2  2.5 4.5  3.0 5.1  2.6 5.2  3.3
N (%)
AD probable 54 (84) 33 (89) 67 (91) 40 (74)
Women 48 (75) 24 (65) 54 (73) 40 (74)
Latinos 25 (39) 15 (41) 29 (39) 30 (56)
Asian Americans 18 (28) 13 (35) 30 (41) 9 (17)
African Americans 15 (23) 4 (11) 10 (14) 9 (17)
Other 6 (9) 5 (14) 5 (7) 6 (11)
Median no. of concomitant meds 2 2 3 3
Median no. of comorbid illnesses 1 1 2 1
Donepezil Treatment in Ethnically Diverse AD Patientspart of ongoing multisite CADC research collabora-
tions7,8 carried out in accordance with all applicable
Institutional Review Board requirements.
Outcome Measures
The primary outcome measure was the 30-point
MMSE,3 used extensively in dementia and drug
research. The MMSE provides a longitudinal “bench-
mark” used by clinicians in different countries and in
different languages9,10 and has been evaluated psy-
chometrically.11,12 The 17-point Blessed-Roth Demen-
tia Rating Scale (BRDRS) was used as a secondary
functional outcome measure.13,14 Higher scores on the
BRDRS indicate greater functional impairment.
Statistical Analysis
For both outcome measures, a t test was performed
to assess differences between the donepezil and no-
donepezil groups in a 1-year change. As discussed
below, supplementary data analyses based on pro-
pensity methods15 and other techniques were carried
out to address the observational nature of this study
in which assignment to treatment is nonrandom. We
wanted to ensure that no signiﬁcant biases were
created by each physician prescribing donepezil ac-
cording to her or his criteria.
To evaluate the possible sources of prescribing bias,
we used a recursive partitioning method based on
examination of the receiver operating characteristic
(ROC), a signal detection technique.16,17 The ROC386method used here was also used in our prior ADwork
in the community setting.18,19 Recursive partitioning
based on ROC/signal detection technique produces a
“decision tree” in which signiﬁcant predictors are
combinedwith “and/or” rules to best predict a binary
outcome, in this case the outcome of being prescribed
donepezil. The methodologic rationale is described in
greater detail elsewhere.20 The ROC analyses were
done using publicly available software (http://www.
stanford.edu/wyesavage/ROC.html). We set the
ROC decision tree methods at a p <0.01 to identify
predictors suggested by the literature that might
explain whether or not subgroups of individuals were
disproportionally prescribed donepezil. These 35
variables included both patient characteristics, such as
baseline cognitive status (MMSE), age at disease
onset, comorbid illnesses, concomitant medications,
years of education, gender, marital status, relation-
ship with caregiver, living arrangement, ethnicity,
and veterans status, as well as nonpatient character-
istics, such as date of baseline assessment and study
site.21,22 All other data analyses were performed using
SAS version 9.1 (SAS Institute, Cary, NC).RESULTS
Patient Flow and Study Completion Rates
One hundred one of the 229 ethnically diverse
patients were prescribed donepezil by their physicianAm J Geriatr Psychiatry 23:4, April 2015
FIGURE 1. AD Patient Flow in the ethnically diverse sample in the California study.
Patients Identified for the study
n =229
No-Donepezil 
Treatment (NN)
n =128
Completed 
Study
n=64
Follow-up MMSE Unavailable, n=21
Donepezil status changed, n=15
Lost to follow-up, n=1
Donepezil
Treatment (ND)
n =101
Did Not Complete 
Study
n=37
Completed 
Study
n=74
Did Not Complete 
Study
n=54
Follow-up MMSE Unavailable, n=44
Donepezil status changed, n=5
Lost to follow-up, n=5
Tinklenberg et al.according to his or her usual criteria and 128 were not
(Table 1). At the 1-year follow-up period, 64 patients
in the donepezil treatment group (63%) and 74 in the
no-donepezil treatment group (58%) had completed
the study (Fig. 1). To be a study completer, the pa-
tient needed to have an MMSE assessment 10e18
months after the baseline visit and have no change in
donepezil status.
To assess possible biases generated between AD
patients who fulﬁlled criteria for completers and
those who did not, we also used ROC analyses to
investigate baseline characteristics in each group.
Results indicated that study completion biases were
primarily due to differences in study partners rather
than clinical characteristics. Speciﬁcally, patients
were more likely to complete the study if their care-
giver was a spouse or relative. Patients who entered
the study with a friend, neighbor, paid caregiver, or
other nonrelative were less likely to complete the
study. Given that there were no signiﬁcant clinical
differences between completers and noncompleters,
the remainder of the results focus on the 138 study
completers.Treatment Outcomes
Ethnically diverse AD patients who completed the
study and received donepezil treatment had anAm J Geriatr Psychiatry 23:4, April 2015average 1-year decline of 2.3 points (standard devi-
ation [SD]: 3.9) on the 30-point MMSE compared with
a 1.7-point (SD: 4.2) decline in the ethnically diverse
completers who received no donepezil or other anti-
AD drugs during the study period (Fig. 2). The dif-
ference in 1-year cognitive decline between the
donepezil treatment versus no-donepezil groups was
not statistically signiﬁcant (t136 ¼ 0.87, p ¼ 0.38). The
overall Cohen effect size23 was e0.15. The ROC an-
alyses indicated two propensity subgroups related to
study site: One subgroup consisted of patients
enrolled at Palo Alto prescribed donepezil less
frequently, and the other subgroup consisted of pa-
tients from the remaining sites who were prescribed
donepezil more frequently.
A general linear model analysis was performed
using the two subgroups as a stratiﬁcation factor.
There were no statistically signiﬁcant differences in
1-year decline between subgroups (F(1,134) ¼ 0.07,
p ¼ 0.79) and no signiﬁcant differences in 1-year
decline between the donepezil and no-donepezil
groups (F(1,134) ¼ 1.96, p ¼ 0.16 for the main effect
of treatment; F(1,134) ¼ 3.02, p ¼ 0.08 for the
treatment  site subgroup interaction). Thus, the
analyses indicated that inclusion of the site factor and
interaction did not bias overall results. There were no
signiﬁcant prescribing biases based on patient
characteristics.387
FIGURE 3. Donepezil treatment in ethnically diverse AD
patients compared with white non-Latino AD
patients from the California study. Donepezil-Wh:
white non-Latino AD patients prescribed
donepezil, study completers (N[ 148); No Donep-
Wh: white non-Latino AD patients not prescribed
donepezil, study completers (N[ 158); Donepezil-
ED: ethnically diverse AD patients prescribed
donepezil, study completers (N [ 64); No Donep-
ED: ethnically diverse AD patients not prescribed
donepezil, study completers (N [ 74).
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FIGURE 2. Mean MMSE scores at baseline and at 1 year for
ethnically diverse AD patients prescribed versus
not prescribed donepezil. Donepezil-ED:
ethnically diverse AD patients prescribed
donepezil, study completers (N [ 64); No Donep-
ED: ethnically diverse AD patients not prescribed
donepezil, study completers (N [ 74).
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Donepezil Treatment in Ethnically Diverse AD PatientsEthnically diverse patients who received donepezil
had an average 1-year increase (decline) of 0.8 points
(SD: 1.8) on the BRDRS compared with an increase
(decline) of 1.4 points (SD: 2.0) in the no-donepezil
treatment group. The difference in functional
decline between the two groups was not statistically
signiﬁcant (t120 ¼ e1.71, p ¼ 0.09). The overall Cohen
effect size23 was 0.31.DISCUSSION
In this prospective observational study, the annu-
alized MMSE changes in ethnically diverse AD pa-
tients were not signiﬁcantly different between those
who received donepezil treatment during the 1-year
study period and those who did not receive done-
pezil or other anti-AD medications. We had initially
hypothesized that there would be some beneﬁt from
donepezil treatment. The lack of beneﬁt was an un-
expected ﬁnding and suggests decreased effective-
ness of donepezil in minority populations. Had we
used multiple imputation with intention to treat, the
differences would have remained not statistically
signiﬁcant.388In contrast, in our ﬁrst California study, which
included only white non-Latino patients but was
otherwise methodologically identical, there was a
modest positive response to donepezil treatment.18
The reasons for these differences are unclear, but
additional research is now underway that may add
clarity. For example, the lack of treatment effective-
ness in the ethnically diverse observational study
might be explained by poorer compliance, which has
reportedly been more common among ethnically
diverse patients.24 Figure 3 shows the slopes of both
the ethnically diverse and non-Latino white patient
groups are similar overall, suggesting the 1-year
cognitive declines are clinically comparable regard-
less of treatment status.
We were fortuitous in the timing of the data
collection in these two prospective observational
studies. In both, the sample collection began on
January 1, 1998, just after donepezil received U.S.
Food and Drug Administration approval in 1997. At
that time, donepezil was not widely prescribed in
California. Sample collection continued to June 30,Am J Geriatr Psychiatry 23:4, April 2015
Tinklenberg et al.2004 when donepezil prescription for AD patients had
become standard of practice for many clinicians. These
temporal changes in the frequency of donepezil pre-
scribing were not so large that they were identiﬁed as
a signiﬁcant source of prescribing bias by the ROC
propensity analyses. Yet, temporal patterns might
have contributed to the roughly equal sizes of the AD
groups receiving donepezil or not receiving it,
providing optimal power to detect differences in
1-year cognitive declines. If there had been an
extremely disproportionate prescription of donepezil,
then the power of the main analysis and the pro-
pensity analyses would have been diminished.25
There are a number of caveats in considering these
two California studies: small sample sizes, particularly
with regard to individual ethnic groups; high rates of
missing outcome data; and medication compliance
concerns.26 However, a key strength of these studies is
that the ﬁndings can be easily understood by clinicians
throughout the world. The MMSE, our primary
outcome measure, is a widely used mental status
assessment tool worldwide. Both the MMSE and a
telephoneversionof themeasure27havebeen translated
into numerous languages, including Persian, Hindi,
Cantonese, Spanish, and Brazilian Portuguese.28e33
Although underscoring methodologic concerns, it
should be emphasized that the ethnically diverse
data presented here represent one of largest system-
atic minority AD drug studies to date. This is
important because minority AD patients have been
under-represented in drug development efforts,
including the “pivotal” FDA trials that are essential
for U.S. marketing approval. Our ﬁndings reinforce
the need for further larger scale studies focused on
speciﬁc ethnic groups. Our ﬁndings do not support
the conclusion that donepezil should not be pre-
scribed to ethnically diverse patients but do suggest
that physicians might consider lowering their ex-
pectations for 1-year donepezil beneﬁts.
These observational ﬁndings from California can be
compared with the landmark 1-year Nordic RCT of
AD treatment with donepezil versus placebo.10 Of
note is that the donepezil-treated California study
group that was ethnically most like the Nordic pa-
tients, white and non- Latino, also had 1-year changes
quite similar to the RCT Nordic ﬁndings.18 Although
there were some instances of statistical signiﬁcance in
these 1-year changes, they are of questionable clinical
importance because of a relatively small effect size. AsAm J Geriatr Psychiatry 23:4, April 2015noted before, the degree of beneﬁt derived from done-
pezil and other cholinesterase inhibitors, particularly in
relation to their ﬁnancial and medical costs, is contro-
versial.34,35 In other words, the efﬁcacy of cholinesterase
inhibitors seen in some RCTs may not translate to
effectiveness in real-world settings.One advantage of the
California observational studies is that results should
generalize into clinical practice more directly than re-
sults from RCTs such as the Nordic study. The AD
subjects included in the California studies were those
who would be treated in a typical community setting;
subjects were not excluded for medical conditions,
concomitant medications, or other enrollment re-
strictions of traditional RCTs involving anti-Alzheimer
drugs. Therefore, the more representative patient sam-
ples that are possible in observational studies can help
provide useful guidance on what the individual
physician can expect in his or her practice when done-
pezil treatment is prescribed for 1 year.
This list of contributors are as follows: California
Alzheimer’s Disease Centers: University of California
DaviseMartinez: B. Reed, K. Vieira; University of Cali-
fornia DaviseSacramento: D. Mungas, C. DeCarli, J.
LaGrande, T. Bloom, R. Sanchez; University of Californiae
Irvine: C. Cotman, R. M. Dick, S. Sirivong, D. Hoang, S.
Mobley; University of CaliforniaeLos Angeles: J. Ringman,
J. Cummings, J. Suarez, K. Metz, S. Hwang, A. Ramirez;
University of CaliforniaeSan Diego: D. Galasko, D.
Salmon, M. Sundsmo, A. Booth; University of Cal-
iforniaeSan Francisco: B. Miller, K. Yaffe, J. Johnson, J.
Kramer, R. Gearhart, C. Barton, J. Hesse; University of
California San FranciscoeFresno: L. Alving, L. Hewett, P.
Conley, A. Sherriffs; University of Southern Californiae
Rancho Los Amigos: F. Segal-Gidan, H. Chui, B. Smith, A.
Ireland, S. Lyness; University of Southern CaliforniaeLos
Angeles: L. Schneider, K. Dagerman, J. Danner, S. Paw-
luczyk, B. Spann; Stanford University/Palo Alto VA
(Coordinating site): H. Davies, P. Luu, T. Miller, L.
Newkirk. Veteran Affairs Mental Illness Research and Ed-
ucation Centers: Martinez: B. Reed, K. Vieira; Palo Alto: J.
Yesavage, E. Gere, S. Joseph, R. O’Hara, E. Wakabayashi;
San Francisco: K. Yaffe, C. Barton, P. Sayegh. Institute of
Health and Aging and Alzheimer’s Disease Program of
California: P. Fox, D. Tyrrell, L. Ross, P. Tang.
Supported in part by the Palo Alto Veterans Institute
for Research, VA Research Program, VA Sierra Paciﬁc
Mental Illness Research and Education Center, the Na-
tional Institute on Aging (grants AG17824 and389
Donepezil Treatment in Ethnically Diverse AD PatientsAG016750), and the Easton Consortium for Alzheimer’s
Disease Drug Discovery and Biomarkers.
Dr. Yaffe reports personal fees from Novartis as a
consultant during the conduct of the study. Outside the
submitted work, Dr. Yaffe is a consultant for Pﬁzer and390serves on Data and Safety Monitoring Boards for
Takeda, Inc.
Presented in part at the 47th annual meeting of
the American College of Neuropsychopharmacology,
Scottsdale, Arizona, December 7e11, 2008.References1. American Psychiatric Association: Diagnostic and Statistical
Manual of Mental Disorders, 4th ed. Washington, DC, American
Psychiatric Association, 1994
2. McKhann G, Drachman D, Folstein M, et al: Clinical diagnosis of
Alzheimer’s disease: report of the NINCDS-ADRDA Work Group
under the auspices of Department of Health and Human Services
Task Force on Alzheimer’s Disease. Neurology 1984; 34:939e944
3. Folstein MF, Folstein SE, McHugh PR: “Mini-Mental State.” A
practical method for grading the cognitive state of patients for
the clinician. J Psychiatr Res 1975; 12:189e198
4. Chui HC, Victoroff JI, Margolin D, et al: Criteria for the diagnosis
of ischemic vascular dementia proposed by the State of California
Alzheimer’s Disease Diagnostic and Treatment Centers.
Neurology 1992; 42:473e480
5. Edwards ER, Lindquist K, Yaffe K: Clinical proﬁle and course of
cognitively normal patients evaluated in memory disorders
clinics. Neurology 2004; 62:1639e1642
6. Chui HC, Mack W, Jackson JE, et al: Clinical criteria for the
diagnosis of vascular dementia: a multicenter study of compara-
bility and interrater reliability. Arch Neurol 2000; 57:191e196
7. Winchester J, Dick MB, Gillen D, et al: Walking stabilizes cogni-
tive functioning in Alzheimer’s disease (AD) across one year.
Arch Gerontol Geriatr 2013; 56:96e103
8. Weinstein AM, Barton C, Ross L, et al: Treatment practices of mild
cognitive impairment in California Alzheimer’s Disease Centers.
J Am Geriatr Soc 2009; 57:686e690
9. Salmon DP, Thal LJ, Butters N, et al: Longitudinal evaluation of
dementia of the Alzheimer type: a comparison of 3 standardized
mental status examinations. Neurology 1990; 40:1225e1230
10. Winblad B, Engedal K, Soininen H, et al: A 1-year, randomized,
placebo-controlled study of donepezil in patients with mild to
moderate AD. Neurology 2001; 57:489e495
11. Galasko D, Abramson I, Corey-Bloom J, et al: Repeated exposure
to the Mini-Mental State Examination and the Information-
Memory-Concentration Test results in a practice effect in Alz-
heimer’s disease. Neurology 1993; 43:1559e1563
12. Mungas D, Reed BR: Application of item response theory for
development of a global functioning measure of dementia with
linear measurement properties. Stat Med 2000; 19:1631e1644
13. Blessed G, Tomlinson BE, Roth M: Blessed-Roth Dementia Scale
(DS). Psychopharmacol Bull 1988; 24:705e708
14. Erkinjuntti T, Hokkanen L, Sulkava R, et al: The Blessed Dementia
Scale as a screening test for dementia. Int J Geriatr Psychiatry
1988; 3:267e273
15. Rubin DB: Estimating causal effects from large data sets using
propensity scores. Ann Intern Med 1997; 127:757e763
16. KraemerHC:EvaluatingMedicalTests.NewburyPark,CA, Sage, 1992
17. Swets JA, Pickett RM: Evaluation of Diagnostic Systems: Methods
fromSignalDetectionTheory.NewYork,NY,AcademicPress, 1982
18. Tinklenberg JR, Kraemer HC, Yaffe K, et al: Donepezil treatment
and Alzheimer disease: can the results of randomized clinical
trials be applied to Alzheimer disease patients in clinical practice?
Am J Geriatr Psychiatry 2007; 15:953e96019. O’Hara R, Thompson JM, Kraemer HC, et al: Which Alzheimer
patients are at risk for rapid cognitive decline? J Geriatr Psychi-
atry Neurol 2002; 15:233e238
20. Kiernan M, Kraemer HC, Winkleby MA, et al: Do logistic
regression and signal detection identify different subgroups at
risk? Implications for the design of tailored interventions. Psychol
Methods 2001; 6:35e48
21. Noda A, Kraemer HC, Taylor JL, et al: Strategies to reduce site
differences in multisite studies: a case study of Alzheimer disease
progression. Am J Geriatr Psychiatry 2006; 14:931e938
22. Yesavage JA, Hoblyn J, Sheikh J, et al: Age and disease severity
predict choice of atypical neuroleptic: a signal detection
approach to physicians’ prescribing decisions. J Psychiatr Res
2003; 37:535e538
23. Cohen J: Statistical Power Analysis for the Behavioral Sciences.
New York, NY, Academic Press, 1969
24. Poon I, Lal LS, Ford ME, et al: Racial/ethnic disparities in medi-
cation use among veterans with hypertension and dementia: a
national cohort study. Ann Pharmacother 2009; 43:185e193
25. Kraemer HC, Thiemann S: How Many Subjects? Statistical Power
Analysis in Research. Newbury Park, CA, Sage, 1987
26. Lanouette NM, Folsom DP, Sciolla A, et al: Psychotropic medi-
cation nonadherence among United States Latinos: a compre-
hensive literature review. Psychiatr Serv 2009; 60:157e174
27. Newkirk LA, Kim JM, Thompson JM, et al: Validation of a 26-point
telephone version of the Mini-Mental State Examination. J Geriatr
Psychiatry Neurol 2004; 17:81e87
28. Ansari NN, Naghdi S, Hasson S, et al: Validation of a Mini-Mental
State Examination (MMSE) for the Persian population: a pilot
study. Appl Neuropsychol 2010; 17:190e195
29. Ganguli M, Ratcliff G, Chandra V, et al: A Hindi version of the
MMSE: the development of a cognitive screening instrument for a
largely illiterate rural elderly population in India. Int J Geriatr
Psychiatry 1995; 10:367e377
30. Chiu HF, Lee HC, Chung WS, et al: Reliability and validity of the
Cantonese version of Mini-Mental State Examination—a pre-
liminary study. J Hong Kong Coll Psychiatr 1994; 4:25e28
31. Garre-Olmo J, Lax-Pericall C, Turro-Garriga O, et al: Adaptation
and convergent validity of a telephone-based Mini-Mental State
Examination. Med Clin (Barc) 2008; 131:89e95
32. Camozzato AL, Kochhann R, Godinho C, et al: Validation of a
telephone screening test for Alzheimer’s disease. Neuropsychol
Dev Cogn B Aging Neuropsychol Cogn 2011; 18:180e194
33. Wong SS, Fong KN: Reliability and validity of the telephone
version of the Cantonese Mini-Mental State Examination (T-
CMMSE) when used with elderly patients with and without de-
mentia in Hong Kong. Int Psychogeriatr 2009; 21:345e353
34. Ringman JM, Cummings JL: Current and emerging pharmaco-
logical treatment options for dementia. Behav Neurol 2006; 17:
5e16
35. Courtney C, Farrell D, Gray R, et al: Long-term donepezil treat-
ment in 565 patients with Alzheimer’s disease (AD2000): rando-
mised double-blind trial. Lancet 2004; 363:2105e2115Am J Geriatr Psychiatry 23:4, April 2015
